Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill AVZO-023 takes on advanced breast cancer in first human trial

NCT ID NCT06998407

Recruiting now Disease control Sponsor: Avenzo Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 5 times

Summary

This study tests a new oral drug called AVZO-023, which blocks a protein (CDK4) that helps cancer cells grow. It is being tested alone or with other drugs in 380 adults with advanced solid tumors, especially a type of breast cancer called HR+/HER2-. The goal is to find a safe dose and see if it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AVZO-023 (a CDK4 inhibitor drug taken by mouth)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced breast cancer or other solid tumors that have stopped responding to current therapies.
What could go wrong
This is an early first-in-human study, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR CCND1 GENE AMPLIFICATION CDK GENE MUTATION CDK4 GENE AMPLIFICATION HR+, HER2-, ADVANCED BREAST CANCER HR+/HER2- BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Los Angeles, California, 90025, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Los Angeles, California, 90095, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    New Haven, Connecticut, 06519, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Orlando, Florida, 32827, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Sarasota, Florida, 34232, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Tampa, Florida, 33612, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    New York, New York, 10016, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Columbus, Ohio, 43221, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Houston, Texas, 77030, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Avenzo Therapeutics Recruiting Site

    RECRUITING

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.